![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RLF |
Gene summary for RLF |
![]() |
Gene information | Species | Human | Gene symbol | RLF | Gene ID | 6018 |
Gene name | RLF zinc finger | |
Gene Alias | ZN-15L | |
Cytomap | 1p34.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q13129 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6018 | RLF | CCI_1 | Human | Cervix | CC | 1.16e-10 | 8.79e-01 | 0.528 |
6018 | RLF | CCI_3 | Human | Cervix | CC | 5.94e-04 | 5.96e-01 | 0.516 |
6018 | RLF | LZE4T | Human | Esophagus | ESCC | 1.63e-13 | 3.07e-01 | 0.0811 |
6018 | RLF | LZE7T | Human | Esophagus | ESCC | 8.02e-03 | 3.46e-01 | 0.0667 |
6018 | RLF | LZE8T | Human | Esophagus | ESCC | 1.34e-02 | 1.55e-01 | 0.067 |
6018 | RLF | LZE20T | Human | Esophagus | ESCC | 2.22e-07 | 1.40e-01 | 0.0662 |
6018 | RLF | LZE22T | Human | Esophagus | ESCC | 1.13e-05 | 2.08e-01 | 0.068 |
6018 | RLF | LZE24T | Human | Esophagus | ESCC | 1.10e-13 | 4.56e-01 | 0.0596 |
6018 | RLF | LZE21T | Human | Esophagus | ESCC | 2.33e-02 | 2.44e-01 | 0.0655 |
6018 | RLF | P1T-E | Human | Esophagus | ESCC | 1.83e-04 | 2.48e-01 | 0.0875 |
6018 | RLF | P2T-E | Human | Esophagus | ESCC | 3.48e-40 | 6.71e-01 | 0.1177 |
6018 | RLF | P4T-E | Human | Esophagus | ESCC | 2.88e-14 | 3.71e-01 | 0.1323 |
6018 | RLF | P5T-E | Human | Esophagus | ESCC | 8.47e-23 | 3.70e-01 | 0.1327 |
6018 | RLF | P8T-E | Human | Esophagus | ESCC | 6.09e-23 | 3.58e-01 | 0.0889 |
6018 | RLF | P9T-E | Human | Esophagus | ESCC | 5.58e-09 | 1.02e-01 | 0.1131 |
6018 | RLF | P10T-E | Human | Esophagus | ESCC | 6.44e-33 | 5.65e-01 | 0.116 |
6018 | RLF | P11T-E | Human | Esophagus | ESCC | 3.66e-18 | 7.08e-01 | 0.1426 |
6018 | RLF | P12T-E | Human | Esophagus | ESCC | 3.53e-25 | 5.81e-01 | 0.1122 |
6018 | RLF | P15T-E | Human | Esophagus | ESCC | 2.25e-23 | 6.02e-01 | 0.1149 |
6018 | RLF | P16T-E | Human | Esophagus | ESCC | 3.78e-17 | 2.69e-01 | 0.1153 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043523110 | Thyroid | PTC | regulation of neuron apoptotic process | 102/5968 | 212/18723 | 5.45e-07 | 8.76e-06 | 102 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:190121518 | Thyroid | PTC | negative regulation of neuron death | 95/5968 | 208/18723 | 2.01e-05 | 2.04e-04 | 95 |
GO:00435245 | Thyroid | PTC | negative regulation of neuron apoptotic process | 66/5968 | 145/18723 | 3.88e-04 | 2.61e-03 | 66 |
GO:007207316 | Thyroid | PTC | kidney epithelium development | 60/5968 | 136/18723 | 1.78e-03 | 9.66e-03 | 60 |
GO:007216313 | Thyroid | PTC | mesonephric epithelium development | 41/5968 | 92/18723 | 7.12e-03 | 3.06e-02 | 41 |
GO:007216413 | Thyroid | PTC | mesonephric tubule development | 41/5968 | 92/18723 | 7.12e-03 | 3.06e-02 | 41 |
GO:000182313 | Thyroid | PTC | mesonephros development | 42/5968 | 96/18723 | 9.53e-03 | 3.91e-02 | 42 |
GO:000165713 | Thyroid | PTC | ureteric bud development | 40/5968 | 91/18723 | 1.02e-02 | 4.14e-02 | 40 |
GO:00182126 | Thyroid | PTC | peptidyl-tyrosine modification | 142/5968 | 378/18723 | 1.02e-02 | 4.14e-02 | 142 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RLF | SNV | Missense_Mutation | novel | c.1436N>A | p.Cys479Tyr | p.C479Y | Q13129 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
RLF | SNV | Missense_Mutation | c.5122G>C | p.Glu1708Gln | p.E1708Q | Q13129 | protein_coding | tolerated(0.22) | benign(0.234) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RLF | SNV | Missense_Mutation | c.3224N>T | p.Ser1075Leu | p.S1075L | Q13129 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
RLF | SNV | Missense_Mutation | rs752951336 | c.2308C>T | p.Arg770Cys | p.R770C | Q13129 | protein_coding | deleterious(0.01) | possibly_damaging(0.854) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RLF | SNV | Missense_Mutation | rs368064385 | c.4372C>T | p.Arg1458Cys | p.R1458C | Q13129 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RLF | SNV | Missense_Mutation | c.388N>C | p.Val130Leu | p.V130L | Q13129 | protein_coding | tolerated(0.07) | benign(0.027) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RLF | SNV | Missense_Mutation | c.2606A>G | p.Asp869Gly | p.D869G | Q13129 | protein_coding | tolerated(0.09) | benign(0.015) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
RLF | SNV | Missense_Mutation | c.2264C>T | p.Ser755Leu | p.S755L | Q13129 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
RLF | SNV | Missense_Mutation | c.2222N>T | p.Pro741Leu | p.P741L | Q13129 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
RLF | SNV | Missense_Mutation | c.5612N>A | p.Cys1871Tyr | p.C1871Y | Q13129 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |